ICAM1 and plasma cell myeloma: Pharmacological inhibition or genetic knockdown of PSGL‐1 or ICAM‐1 signaling in these myeloma cells can diminish the protective effects of TAMs from cytotoxic cancer‐killing agents including melphalan, doxorubicin, and bortezomib.